Oppenheimer Defends Acasti Pharma (ACST), Seeing Buying Opportunity
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $7.00 price target on Acasti Pharma (NASDAQ: ACST)The analyst comments "With ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE